Emerging Trends in the MET Oncology Market
These innovative therapeutic agents predominantly target MET-altered non-small cell lung cancer (NSCLC), particularly tumors displaying MET exon 14 skipping mutations or MET amplifications, where abnormal MET signaling promotes tumor expansion, survival, and metastatic spread
